Aflibercept
ApprovedUNKNOWN 0 watching 0 views this week๐ฅ Hot
84
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Age Related Macular Degeneration
Conditions
Age Related Macular Degeneration, Pigment Epithelial Detachment
Trial Timeline
Aug 1, 2012 โ Jan 1, 2016
NCT ID
NCT01670162About Aflibercept
Aflibercept is a approved stage product being developed by Regeneron Pharmaceuticals for Age Related Macular Degeneration. The current trial status is unknown. This product is registered under clinical trial identifier NCT01670162. Target conditions include Age Related Macular Degeneration, Pigment Epithelial Detachment.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01714115 | Pre-clinical | Completed |
| NCT04101721 | Phase 3 | Completed |
| NCT03396861 | Phase 1 | Terminated |
| NCT03085784 | Phase 2 | UNKNOWN |
| NCT02863354 | Phase 2 | Completed |
| NCT02559180 | Approved | Completed |
| NCT02503540 | Approved | Completed |
| NCT02299336 | Approved | Completed |
| NCT02204683 | Phase 1 | Completed |
| NCT01857544 | Approved | UNKNOWN |
| NCT01722656 | Approved | Completed |
| NCT01670162 | Approved | UNKNOWN |
| NCT01617148 | Approved | Completed |
| NCT01495208 | Approved | Withdrawn |
Competing Products
20 competing products in Age Related Macular Degeneration